ONE PAGER SHIKSHAN NIVESH

Krsnaa Diagnostics

SECTOR: DIAGNOSTIC SERVICES (RADIOLOGY & PATHOLOGY)

Company Overview

Krsnaa Diagnostics Ltd. is a **leading diagnostic service provider** specializing in radiology, pathology, and teleradiology. Operating in **18+ states** with **3,000+ centers,** the company focuses on affordable, high-quality diagnostics, mainly through the **Public-Private Partnership (PPP) model.**

Financial Performance Q3 FY25

krsnaa

✓ Revenue: ₹531.1 crore (+17% YoY) – Growth driven by test volume increase & new PPP contracts.
 ✓ Net Profit: ₹56.9 crore (9M FY25 profit already matches full-year FY24).
 ✓ EBITDA: ₹141.6 crore (+39% YoY); EBITDA Margin: 27% (vs. 25% in FY24).
 ✓ Debt Levels: Net debt-free, ensuring financial stability

NIVESH

AN

Cash Flow: Healthy despite increased receivables from Himachal Pradesh & Karnataka

Strategic Growth Areas

Strategic Growth Areas	
 PPP & Government Contracts 	 40 CT scan machines commissioned in Maharashtra (Dec 2024) 17 MRI centers launching in Q1 FY26 Jharkhand PPP project in progress
ං් Retail Expansion (RPL Brand)	 Expansion Maharashtra, Punjab, Assam, Odisha Growing demand for preventive health & wellness packages
💡 Al & Digital Health Innovations	 Al-powered diagnostics & automation improving efficiency Home collection services & online health platforms expanding

Investment Takeaway

Strengths: Market leader in PPP, retail expansion, Al-driven efficiency, debt-free balance sheet.

▲ Challenges: Contract renewals, regulatory risks, rising competition in retail diagnostics.
 ✓ Verdict: Sustained long-term growth (~15% CAGR), but execution risks remain key watchpoints.

Market Cap

₹ 2.282 Cr.

Investment Risks

Project Delays: Maharashtra & MP MRI centers rollout slower than expected Tax Liabilities: ₹19.63 Cr tax demand under
 appeal (IT Dept.) A Revenue Variability: Loss of Mumbai BMC contract impacted Q3 FY25 ① Operational Challenges: Issues in Karnataka & Assam affecting volumes △ Competitive Pressure: Retail diagnostics space faces stiff competition from Dr. Lal PathLabs, Metropolis, SRL ales CAGR 5 Year Enterprise Value PEG Ratio 32% 0.78 ₹ 2.437 Cr.

Outlook: A long-term healthcare growth play with strong cash flows & expansion potential.

Source: Krsnaa Diagnostics Q3 FY25 concall transcript (Feb 2025), Company Annual Report FY24, ICRA rating report (Apr 2024), Company Website, SEBI/BSE filings.

Krsnaa

Diagnostics

One Pager

Brought to you by Shikshan Nivesh

, 19

@@shikshan_nivesh 💉 @ShikshanNivesh